Pharmaron Beijing Co., Ltd.
SZSE:300759.SZ
27.61 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 11,455.244 | 10,266.288 | 7,443.77 | 5,133.597 | 3,757.16 | 2,908.123 | 2,294.118 | 1,634.239 | 1,128.038 | 790.44 |
| Cost of Revenue
| 7,654.234 | 6,497.89 | 4,764.854 | 3,210.075 | 2,422.783 | 1,963.456 | 1,543.105 | 1,160.228 | 817.639 | 592.094 |
| Gross Profit
| 3,801.011 | 3,768.398 | 2,678.916 | 1,923.522 | 1,334.377 | 944.667 | 751.013 | 474.011 | 310.398 | 198.346 |
| Gross Profit Ratio
| 0.332 | 0.367 | 0.36 | 0.375 | 0.355 | 0.325 | 0.327 | 0.29 | 0.275 | 0.251 |
| Reseach & Development Expenses
| 418.604 | 282.325 | 151.775 | 105.345 | 62.872 | 31.611 | 22.608 | 16.444 | 0 | 0 |
| General & Administrative Expenses
| 752.133 | 739.415 | 254.823 | 295.641 | 222.419 | 128.227 | 127.239 | 123.495 | 112.068 | 143.394 |
| Selling & Marketing Expenses
| 252.778 | 230.07 | 155.617 | 92.643 | 72.989 | 54.655 | 47.163 | 32.038 | 16.435 | 11.865 |
| SG&A
| 1,684.176 | 969.485 | 410.44 | 388.284 | 295.407 | 182.882 | 174.402 | 155.533 | 128.503 | 155.259 |
| Other Expenses
| -8.566 | 766.002 | 591.844 | 345.314 | 271.956 | 20.463 | 15.55 | 24.671 | 14.602 | 6.054 |
| Operating Expenses
| 2,111.346 | 2,017.812 | 1,154.058 | 838.943 | 630.235 | 503.535 | 388.853 | 286.004 | 224.978 | 156.866 |
| Operating Income
| 1,689.665 | 1,689.892 | 1,914.337 | 1,323.835 | 631.487 | 380.046 | 262.966 | 189.837 | 72.912 | 24.615 |
| Operating Income Ratio
| 0.148 | 0.165 | 0.257 | 0.258 | 0.168 | 0.131 | 0.115 | 0.116 | 0.065 | 0.031 |
| Total Other Income Expenses Net
| 150.306 | -23.5 | -3.342 | -4.465 | 1.065 | -40.624 | -83.644 | 26.502 | 2.093 | -12.571 |
| Income Before Tax
| 1,839.971 | 1,666.391 | 1,910.996 | 1,319.369 | 632.552 | 400.509 | 278.516 | 214.508 | 87.514 | 28.909 |
| Income Before Tax Ratio
| 0.161 | 0.162 | 0.257 | 0.257 | 0.168 | 0.138 | 0.121 | 0.131 | 0.078 | 0.037 |
| Income Tax Expense
| 256.106 | 314.254 | 290.919 | 172.378 | 101.878 | 61.483 | 51.492 | 37.596 | 13.668 | 7.914 |
| Net Income
| 1,601.096 | 1,374.604 | 1,661.029 | 1,172.382 | 547.191 | 339.224 | 230.857 | 176.912 | 73.846 | 20.995 |
| Net Income Ratio
| 0.14 | 0.134 | 0.223 | 0.228 | 0.146 | 0.117 | 0.101 | 0.108 | 0.065 | 0.027 |
| EPS
| 0.9 | 0.78 | 0.93 | 0.66 | 0.37 | 0.38 | 0.26 | 0.23 | 0.38 | 0.042 |
| EPS Diluted
| 0.9 | 0.77 | 0.91 | 0.66 | 0.37 | 0.38 | 0.26 | 0.23 | 0.38 | 0.042 |
| EBITDA
| 2,698.253 | 2,614.392 | 2,597.279 | 1,629.709 | 1,024.63 | 700.552 | 486.938 | 323.729 | 173.243 | 97.999 |
| EBITDA Ratio
| 0.236 | 0.255 | 0.349 | 0.317 | 0.273 | 0.241 | 0.212 | 0.198 | 0.154 | 0.124 |